Mobile PET Systems and Bracco Diagnostics Form Cardiac PET Partnership.

Business Editors & Health/Medical Writers

SAN DIEGO--(BUSINESS WIRE)--Oct. 10, 2002

Mobile PET Systems Inc. (OTCBB:MBPT), a leading provider of Positron Emission Tomography (PET) imaging services to health care entities and Bracco Diagnostics Inc., the Princeton-based US operating company of the Bracco Group, world leader in global integrated solutions for diagnostic imaging, the supplier of CardioGen-82(R), a cardiac Rubidium 82 infusion system product, today agreed to establish a strategic partnership pilot program designed to jointly provide cardiac PET products and services to health care providers.

Under this pilot program Bracco Diagnostics Inc. and Mobile PET Systems Inc., have agreed to combine their marketing and sales resources to offer cardiovascular PET services to cardiology groups in the United States.

Carlo Medici, president and CEO of Bracco Diagnostics Inc., shared his enthusiasm for the collaboration, "Bracco is very excited about this co-marketing program with Mobile PET Systems Inc. The combination of our proprietary PET myocardial perfusion agent, CardioGen-82(R), and Mobile PET Systems Inc.'s quality imaging service will bring this state-of-the-art technology to community cardiologists and their patients who previously did not have access to the PET imaging technology. This will enable more cardiologists to diagnose coronary artery disease with greater accuracy than other non-invasive imaging procedures and improve the overall level of patient care."

"More than 1.5 million Americans have acute myocardial infarctions each year," commented Paul J. Crowe, president and CEO of Mobile PET Systems. "Up to 13% of middle-aged men in the U.S. have coronary arteriosclerosis, most of it clinically silent. Over 600,000 deaths are attributed to or is the result of myocardial infarctions. The major question for cardiovascular medicine is how to detect and identify silent coronary artery disease (CAD) in specific individuals and how to define its severity in either the symptomatic or asymptomatic patient. We believe that Rb-82 PET, the gold standard in cardiac imaging, is the answer."

Cardiac PET, utilizing the CardioGen-82(R) Rb-82 radiopharmaceutical in MPI (Myocardial Perfusion Imaging), was first reimbursable by Medicare in 1995. Requiring no on-line cyclotron, the Rb-82 infusion system is readily available on a 24 hour / 7 day basis to cardiologists and their patients. A cardiac PET rest/stress study by rubidium 82 provides not only myocardial perfusion results, but also myocardial viability in less than 45 minutes. (Conventional nuclear medicine SPECT cameras would take 4-5 hours to perform this same procedure.)

Crowe added, "Bracco Diagnostics has already identified multiple stationary and mobile cardiac PET opportunities. We believe these opportunities, will best be served by the synergy and blend of our respective organization's products and services."

About PET

Positron Emission Tomography (PET) is a medical imaging procedure that displays metabolic and functional characteristics of disease. Other conventional imaging procedures such as X-Ray, Computerized Axial Tomography (CT), Diagnostic Ultrasound, or Magnetic Resonance Imaging (MRI) systems provide physicians with anatomical information. Because diseases like cancer, cardiac and neurological disorders often exhibit altered metabolism before the anatomy is changed, PET helps physicians effectively detect and stage these problems at their earliest stages. That information helps define and guide appropriate treatment options, which can eliminate redundant testing, hospitalization, or non-beneficial therapies.

About Bracco Diagnostics Inc.

Bracco Diagnostics Inc. is a member of the Bracco Group, a highly innovative healthcare group, world leader in global integrated solutions for diagnostic imaging with 70 years of experience worldwide. Headquartered in Milan, Italy, the Bracco Group consists of six fully owned operations and two joint ventures in Europe, Asia, and the U.S. Bracco Diagnostics, located in Princeton, N.J., is responsible for developing new clinical agents, filing them with regulatory agencies, and selling and marketing all Bracco products in the U.S. For further information, contact their Web site at www.bracco.com.

About Mobile PET Systems Inc.

Mobile PET Systems Inc., based in San Diego, is a leading service provider of Positron Emission Tomography (PET) imaging services in the United States. Our medical service business enables hospitals and other healthcare professionals the ability to access and provide this advanced diagnostic imaging patient service efficiently. Under a service agreement, Mobile PET provides state-of-the-art PET imaging systems, which are integrated into mobile coaches or stationary PET centers. We provide licensed technical personnel who operate the equipment and perform the PET imaging procedure, daily operations and logistical management. The company's clinical Web site, www.PETadvances.com, addresses questions about the various cancers and how molecular imaging can assist and benefit physicians and their patients. For further information contact www.mobilepet.com or telephone [phone].

Certain statements contained in this press release are "forward-looking statements" within the meaning of applicable federal securities laws, including, without limitation, anything relating or referring to future financial results and plans for future business development activities, and are thus prospective. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified based on current expectations. Such risks and uncertainties include, without limitation, the risks and uncertainties set forth from time to time in reports filed by the company with the Securities and Exchange Commission. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward the forward-looking statements contained herein. The companies undertake no obligation to publicly release statements made to reflect events or circumstances after the date hereof.